SIBN - SI-BONE, Inc.
The consensus price target hints at a 65.3% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
SI-BONE, Inc. (SIBN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
SI-BONE, Inc. (SIBN) Q1 2026 Earnings Call Transcript
SiBone NASDAQ: SIBN raised its full-year 2026 outlook after reporting double-digit revenue growth in the first quarter, with management pointing to new product launches, expanding physician adoption, international momentum and a proposed Medicare reimbursement change as key drivers for the year ahead.
Si-Bone (SIBN) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.15 per share a year ago.
Delivered ~11% worldwide revenue growth, record physician engagement and ~440% improvement in adjusted EBITDA Delivered ~11% worldwide revenue growth, record physician engagement and ~440% improvement in adjusted EBITDA
Leading contributors in the First Eagle Small Cap Opportunity Fund this quarter included Ultra Clean Holdings, Oil States International, Lincoln Educational Services, Advanced Energy and FormFactor. Oil States International shares rallied on very strong bookings during the quarter and improved operator-powered solutions and services inside the wellbore. The leading detractors in the quarter were Vital Farms, Alphatec Holdings, Beta Bionics, SI-BONE. and Herc Holdings.
SANTA CLARA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming 2026 BofA Securities Healthcare Conference in Las Vegas, NV. Management will be hosting a fireside chat on Tuesday, May 12, 2026, at 8:00 a.m. Pacific Time/11:00 a.m. Eastern Time.
SANTA CLARA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the first quarter of 2026 after market close on Monday, May 11, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time
SiBone (NASDAQ: SIBN - Get Free Report)'s share price was down 6.8% during trading on Friday. The company traded as low as $12.82 and last traded at $12.7650. Approximately 417,589 shares changed hands during mid-day trading, a decline of 31% from the average daily volume of 607,897 shares. The stock had previously closed at $13.69.
JPMorgan Chase and Co. decreased its stake in SiBone (NASDAQ: SIBN) by 32.1% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 185,619 shares of the company's stock after selling 87,788 shares during the period. JPMorgan Chase and Co.
Shares of SiBone (NASDAQ: SIBN - Get Free Report) hit a new 52-week low during trading on Friday. The stock traded as low as $12.47 and last traded at $12.5850, with a volume of 33378 shares changing hands. The stock had previously closed at $12.84. Wall Street Analysts Forecast Growth Several equities research analysts have
Si-Bone (SIBN) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.11 per share a year ago.
SI-BONE, Inc. (SIBN) Q4 2025 Earnings Call Transcript
Achieves 20% worldwide revenue growth and positive adjusted EBITDA for Fiscal Year 2025Generates free cash flow in the Fourth Quarter 2025
SANTA CLARA, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. Management will be hosting a fireside chat on Monday, March 2, 2026, at 7:30 a.m. Pacific Time/ 10:30 a.m. Eastern Time.
Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Shares of SiBone (NASDAQ: SIBN - Get Free Report) have been assigned an average rating of "Moderate Buy" from the seven brokerages that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy
SANTA CLARA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the fourth quarter and full year ended December 31, 2025 after market close on Monday, February 23, 2026.